Atrial FIbrillation Treatment With Cryoballoon in Heart failurE (AFICHE)

Overview

In this study 404 patients with heart failure and an ejection fraction of 0.40 or less, with paroxysmal atrial fibrillation, will be randomly assigned to standard treatment or standard treatment plus a session of cryoballoon ablation (left atrial balloon cryoablation for pulmonary vein isolation). All patients with either have an ICD or CRT-D/P device implanted or an implantable electrocardiographic monitoring device. The primary study endpoint will be the time to AF burden exceeding 1% over any 30-day period (calculated as the ratio of time spent in AF over total time).16 This AF burden corresponds to 7.2 hours per month. A powered secondary endpoint will be the time to the composite of all-cause mortality and unplanned hospitalization for heart failure.

Full Title of Study: “Effect of Cryoballoon Pulmonary Vein Isolation on Atrial Fibrillation Burden and Clinical Endpoints in Patients With Heart Failure With Impaired Left Ventricular Systolic Function”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2021

Interventions

  • Procedure: Cryoballoon ablation
    • Left atrial ablation using cryoballoon to achieve pulmonary vein isolation

Arms, Groups and Cohorts

  • Experimental: Cryoballoon ablation
    • A 28-mm cryoballoon (Arctic Front Advance™ Cardiac CryoAblation Catheter, Medtronic, Minneapolis, MN) will be employed. The cryoballoon catheter will be introduced into the left atrium, following a single transeptal puncture, through a 12F FlexCath steerable sheath (Medtronic), constantly flushed with heparinized saline. A circular mapping catheter (Achieve, Medtronic) will be advanced through the cryoballoon to the PV orifice and positioned as proximally as possible inside the vessel to record the PV potentials at baseline and monitor the isolation procedure in real time.
  • No Intervention: Standard treatment
    • Standard treatment, including at least one rhythm control medication, on top of optimized rate control and HF treatment

Clinical Trial Outcome Measures

Primary Measures

  • Time to exceed AG burden cut-off of 1%
    • Time Frame: Up to 2 years
    • The time to AF burden exceeding 1% over any 30-day period (calculated as the ratio of time spent in AF over total time)

Secondary Measures

  • All-cause mortality or hospitalization for heart failure
    • Time Frame: Up to 2 years
    • Time to the composite of all-cause mortality and unplanned hospitalization for heart failure

Participating in This Clinical Trial

Inclusion Criteria

  • A minimum of at least two separate AF episodes recorded within the last 12 months, either on 12-lead rest ECG or on ambulatory ECG recordings (at least 5 minutes of AF on Holter recordings will be required), – LVEF <40% on sinus rhythm, – symptoms consistent with heart failure (New York Heart Association II or higher) despite rate control treatment, – age >21 years old. Exclusion criteria:

  • previous left atrial ablation, – left atrial diameter >28 mm/m2 BSA on TTE (parasternal long axis view), – strong clinical suspicion that reduced LVEF is primarily due to tachycardiomyopathy, – pre-existing device (ICD or CRT) without AF detection algorithms and/or (for CRT devices) diagnostics of effective biventricular pacing, – known primary electrical heart disease (e.g. Brugada syndrome), – presence of thrombus in a heart chamber, – presence of prosthetic valve at any position, – moderate/severe valvular heart disease, – active infectious disease or malignancy, – moderate or severe hepatic impairment (Child-Pugh class B or C), – severe renal failure (estimated glomerular filtration rate <20 ml/min/1.73 m2), – inability or unwillingness to adhere to standard treatment or to provide consent.

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • G.Gennimatas General Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Spyridon Deftereos, Professor of Cardiology – National and Kapodistrian University of Athens

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.